KalVista Pharmaceuticals Inc (STU:4XC1)
€ 9.2 -0.5 (-5.15%) Market Cap: 456.06 Mil Enterprise Value: 296.04 Mil PE Ratio: 0 PB Ratio: 2.56 GF Score: 34/100

Kalvista Pharmaceuticals Inc at H C Wainwright Hereditary Angioedema (HAE) Conference (Virtual) Transcript

Jul 20, 2022 / 04:00PM GMT
Release Date Price: €12.51 (+7.61%)
Andrew S. Fein
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

Hi, everyone. I'm Andrew Fein, one of the biotech analysts at H.C. Wainwright. Thank you very much for joining us on our HAE Day event. Next presenting will be KalVista. From KalVista, we have Andy, Chris and Ben, senior management team. So we can just dive right into it.

Questions & Answers

Andrew S. Fein
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

I mean it's been an interesting day from a physician perspective, I'd say. We've heard one major academician who was quite willing to switch patients from prophylactic treatment to acute treatment and didn't seem to have necessarily a lot of stickiness to any particular treatment; and another physician who was a bit stickier, I'd say, in terms of lack of willingness to perhaps shift patients if they're doing perfectly fine.

So I guess, Andy or any of you guys, how does that jibe with what you guys have diligence from

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot